Biofrontera

Biofrontera AG is a biopharmaceutical company that develops, sells, and distributes dermatological drugs and medical cosmetics.In December 2022, Biofrontera AG established a subsidiary Biofrontera UK Ltd. to continue the commercialisation of Ameluz in the United Kingdom.In December 2021, Biofrontera Inc announced that the majority ownership of Biofrontera AG was diluted below 50% resulting in 47% of the currently outstanding shares.In March 2019, Biofrontera entered into an agreement to acquire all shares in Cutanea Life Sciences from Maruho, for an initial purchase price of $1.00. Later that month, Biofrontera had acquired 100% of the stock of Cutanea, through its subsidiary Biofrontera Newderm LLC.In July 2003, bioLeads was acquired by Biofrontera Pharmaceuticals Holding AG, and all assets and activities were incorporated into a second subsidiary called Biofrontera Discovery GmbH; however, in April 2005, the Biofrontera Discovery's assets was acquired by